Selected article for: "administration method and lopinavir ritonavir"
Author: Kang, Ji Eun; Rhie, Sandy Jeong
Title: Practice considerations on the use of investigational anti‐COVID‐19 medications: Dosage, administration and monitoring
  • Cord-id: 4wly1s1p
  • Document date: 2020_6_11
    • ID: 4wly1s1p
    Snippet: WHAT IS KNOWN AND OBJECTIVE: Understanding investigational medications is important. Many older drugs are being investigated for repurposing against COVID‐19. We comment on various drugs currently undergoing such trials to optimize their safe use. COMMENT: We describe medications used during early COVID‐19 outbreaks in South Korea, focusing on practice aspects including the method of drug administration, drug formulation, patient‐monitoring for adverse reactions and drug interactions infor
    Document: WHAT IS KNOWN AND OBJECTIVE: Understanding investigational medications is important. Many older drugs are being investigated for repurposing against COVID‐19. We comment on various drugs currently undergoing such trials to optimize their safe use. COMMENT: We describe medications used during early COVID‐19 outbreaks in South Korea, focusing on practice aspects including the method of drug administration, drug formulation, patient‐monitoring for adverse reactions and drug interactions informed by our experience during the 2015 outbreak of Middle East respiratory syndrome (MERS). We comment on hydroxychloroquine, chloroquine, lopinavir/ritonavir with zinc supplement, remdesivir, tocilizumab, ciclesonide, niclosamide and high‐dose intravenous immunoglobulin (IVIG). WHAT IS NEW AND CONCLUSION: Effective therapies are urgently needed to manage COVID‐19, and existing drugs such as antivirals and antimalarials are under investigation for repurposing to meet this need. This process requires up‐to‐date drug information to ensure optimum use, particularly safety and efficacy profiles of the medications, until convincing evidence is reported.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory distress syndrome and administration route: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory distress syndrome and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory distress syndrome and liver enzyme: 1, 2, 3, 4, 5, 6
    • acute respiratory distress syndrome and liver renal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory distress syndrome and liver renal function: 1, 2, 3
    • acute respiratory distress syndrome and lopinavir mg ritonavir: 1, 2, 3
    • acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64
    • additional agent and administration route: 1
    • administration route and liver damage: 1, 2
    • administration route and liver enzyme: 1
    • administration route and lopinavir ritonavir: 1
    • administration route and low oral bioavailability: 1, 2
    • liver damage and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • liver enzyme and lopinavir ritonavir: 1, 2, 3, 4
    • liver renal and lopinavir mg ritonavir: 1
    • liver renal and lopinavir ritonavir: 1, 2, 3, 4, 5